| Drug Name: | bazedoxifene (198481-32-2) |
|---|---|
| PubChem ID: | 154257 |
| SMILES: | CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O |
| InchiKey: | UCJGJABZCDBEDK-UHFFFAOYSA-N |
| Therapeutic Category: | Bone Density Conservation Agents, Estrogen Receptor Modulators, Hormone Antagonists, Hormones, Selective Estrogen Receptor Modulators |
| Molecular Weight (dalton) | : | 470.613 |
| LogP | : | 6.33102 |
| Ring Count | : | 4 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 57.86 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Imatinib (152459-95-5) | Gallstones | Synergistic | Imatinib is reported to increase plasma oestrogen levels by inhibiting its metabolism by the cytochrome P450 isoenzyme CYP3A4 | Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development? |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category